Omeros Corporation - Still Looking Too Risky For A Buy Rating
- Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's lack of profitability. The company was awarded $6.69 million from the National Institute on Drug Abuse for its program OMS527, which focused on the treatment of cocaine use disorder. However, it also has $344 million in long-term debts. Omeros' future heavily relies on FDA approval of its drug candidates, particularly Narsoplimab, and faces intense competition in the biopharmaceutical sector.
- 07/21/2023
|
Omeros Announces Webcast Details for Annual Meeting of Shareholders
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 23, 2023, starting at 10:00 a.m. Pacific Time. A live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2023. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting. A.
- 06/21/2023
|
Why Shares of Omeros Dropped on Monday
- The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash.
- 06/12/2023
|
Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript
- Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Nadia Dac - Chief Commercial Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Greg Harrison - Bank of America Elliott Bosco - UBS Brandon Folkes - Cantor Fitzgerald Operator Good afternoon, and welcome to today's earnings call from Omeros Corporation. At this time, all participants are in a listen-only mode.
- 05/09/2023
|
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone.
- 05/04/2023
|
Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript
- Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Dr. Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Nadia Dac - Vice President and CCO Conference Call Participants Colin Bristow - UBS Steve Brozak - WBB Securities Mary Kate - Bank of America Brandon Folkes - Cantor Serge Belanger - Needham & Company Operator Good afternoon. And welcome to today's earnings call from Omeros Corporation.
- 03/13/2023
|
Why Omeros Stock Bolted Higher This Week
- A $200 million milestone payment sparked a rally in the biopharma's shares this week.
- 02/09/2023
|
Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy
- Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang some investors were worried about. With the additional $200M cash, now the enterprise value of the company is around $115M, which we believe is still very cheap for the company's compelling MASP-2 platform.
- 02/08/2023
|
OMER Stock: Over 50% Surge Explained
- The stock price of Omeros Corporation (NASDAQ: OMER) surged by over 50% intraday today. This is why.
- 02/06/2023
|
Why Omeros Corporation Stock Is Skyrocketing Today
- The Omeros will now be able to fund operations at least through 2025.
- 02/06/2023
|
Best Penny Stocks To Buy: 5 To Watch With Big News This Week
- Penny stocks to watch with big news this week. The post Best Penny Stocks To Buy: 5 To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/06/2023
|
Omeros: Worst Has Been Priced In, We Like Its IgAN Pipeline, Initiating With A Buy
- Omeros corporation's hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) should be considered a free option at this point. Narsoplimab has highly compelling phase 2 data on IgAN and a compelling mechanistic rationale.
- 02/04/2023
|
Omeros' Deafening Silence
- During its Q3 earnings call, Omeros reported on FDA's initial response to its CRL appeal, setting the stage for progress towards approval. Frustratingly, Omeros has not uttered a peep since its Q3 2022 earnings report.
- 12/27/2022
|
Omeros Corporation (OMER) Q3 2022 Earnings Call Transcript
- Omeros Corporation (NASDAQ:OMER ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Conference Call Participants Colin Bristow - UBS Steve Brozak - WBB Securities Eric Joseph - JPMorgan Mary Kate - Bank of America Brandon Folkes - Cantor Serge Belanger - Needham. Operator Good afternoon and welcome to today's earnings call for Omeros Corporation.
- 11/09/2022
|
Omeros: FDA Appeal On Narsoplimab And Several 2023 Catalysts On Deck
- FDA appeal decision by OND of Narsoplimab for the treatment of patients with HSCT-TMA should be coming in the next few months. Results from the phase 3 ARTEMIS-IGAN study, using Narsoplimab for the treatment of patients with IgA Nephropathy are expected in mid-2023.
- 11/01/2022
|
Omeros: Taking It To The Max
- Omeros stock has been drifting with a downward bias since it reported its Q4 2021 earnings. Its problem stems from its protracted delay in getting FDA approval of its narsoplimab in treatment of HSCT-TMA.
- 10/05/2022
|
Omeros: Off To Never-Never Land
- Omeros' lead therapy, narsoplimab in treatment of High-Risk HSCT-TMA, has fumbled repeatedly in front of the FDA. The FDA's latest chapter in this ongoing saga spells progress with a likely high dose of delay.
- 08/19/2022
|
Omeros Corporation (OMER) CEO Gregory Demopulos on Q2 2022 Results - Earnings Call Transcript
- Omeros Corporation. (NASDAQ:OMER ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Nadia Dac - Chief Commercial Officer Conference Call Participants Greg Harrison - Bank of America Steve Brozak - WBB Hannah Adeoye - JPMorgan Brandon Folkes - Cantor Fitzgerald Operator Good afternoon and welcome to today's earnings call for Omeros Corporation.
- 08/09/2022
|
Why Omeros Corporation Stock Is Marching Higher Today
- A positive regulatory development is powering the biotech's shares higher today.
- 07/29/2022
|
Why Omeros Stock Is Freefalling Today
- It's reverting to where it was before its massive uptick last week.
- 07/05/2022
|
Omeros: On Death's Door
- Omeros shareholders have watched with dismay as its share price languishes ever lower. Omeros' $200 million OMIDRIA milestone is cloaked in uncertainty.
- 06/02/2022
|
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2022 Results - Earnings Call Transcript
- Omeros Corporation (NASDAQ:OMER ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Conference Call Participants Eric Joseph - JPMorgan Greg Harrison - Bank of America Brandon Folkes - Cantor Fitzgerald Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.
- 05/10/2022
|
Omeros: The Weight Of The Wait, A Conundrum
- Omeros' OMIDRIA sale has substantially improved its financial prospects. Omeros' CRL gangplank is agonizing for shareholders as they wait for FDA response to its type A meeting.
- 05/02/2022
|
Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript
- Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript
- 03/01/2022
|
Why Earnings Season Could Be Great for Omeros (OMER)
- Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/28/2022
|
Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
- Omeros was handed a CRL for narsoplimab. The lack of clarity surrounding the CRL is disconcerting.
- 02/21/2022
|
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA
- Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised by the FDA.
- 01/20/2022
|
Do Options Traders Know Something About Omeros (OMER) Stock We Don't?
- Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.
- 12/15/2021
|
Omeros: A New Year Beckons
- Omeros' 2021 was a year to forget with the stock dropping during the year all the way from >$23 to below $6.00.
- 12/06/2021
|
Omeros (OMER) Stock: Why The Price Jumped Today
- The stock price of Omeros Corporation (NASDAQ: OMER) increased by over 7% during intraday trading. This is why it happened.
- 12/02/2021
|
Omeros Offloads Cataract Med Omidria To Rayner Surgical In Deal Valued Over $1B
- Omeros Corporation (NASDAQ: OMER) has agreed to sell Omidria to Rayner Surgical Group Limited for an upfront payment of $125 million with an additional $200 million in commercial milestones. Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is approved for use during cataract surgery or intraocular lens replacement to maintain pupil size and reduce postoperative ocular pain.
- 12/02/2021
|
Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2021 Results - Earnings Call Transcript
- Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Omeros: Q3 Earnings Insights
- Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
- 11/09/2021
|
Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years
- Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy. Treatment with narsoplimab showed a median reduction in proteinuria of 64.4%.
- 11/05/2021
|
Wall Street Analysts See a 192% Upside in Omeros (OMER): Can the Stock Really Move This High?
- The average of price targets set by Wall Street analysts indicates a potential upside of 192% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 11/04/2021
|
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021, on Tuesday, November 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via ph
- 11/04/2021
|
3 Beaten-Down Biotech Stocks -- Can They Recover?
- Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year.
- 10/31/2021
|
Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA
- The FDA issued a Complete Response Letter (CRL) related to Omeros Corporation's (NASDAQ: OMER) marketing application for narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Related: Why Are Omeros Shares Plunging On Friday?
- 10/18/2021
|
Here's Why Omeros Is Sinking Further Today
- Bad news the company received today from the FDA surprised investors more than it probably should have.
- 10/18/2021
|
OMER Stock: Why The Price Fell Today
- The stock price of Omeros Corporation (NASDAQ: OMER) fell by over 16% pre-market today. This is why it happened.
- 10/18/2021
|
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Following HSCT, patients generally have complex clinical courses and are often severely ill. HSCT-TMA increases that complexity and worsens outc
- 10/18/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Robert S.
- 10/15/2021
|
OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #Omeros--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) on behalf of Omeros stockholders. Our investigation concerns whether Omeros has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 1, 2021, Omeros announced that the U.S. Food and Drug Admini
- 10/07/2021
|
OMER EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMER
- NEW YORK, Oct. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Omeros Corporation (NASDAQ: OMER) resulting from allegations that Omeros may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Omeros securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 10/07/2021
|
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, Oct. 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or "the Company") (NASDAQ: OMER) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/07/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $OMER #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Omeros investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws
- 10/06/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $OMER #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) investors concerning the Company's possible violations of federal securities laws. On October 1, 2021, Omeros announced that the U.S. Food and Drug Administration (“FDA”) had identified deficiencies with the Company's Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transpl
- 10/05/2021
|
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $OMER #OMER--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation.
- 10/05/2021
|
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Omeros Corporation and Encourages Investors With Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $OMER #OMER--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation.
- 10/04/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 10/01/2021
|
OMER Stock Price: Why It Substantially Fell Today
- The stock price of Omeros Corporation (Nasdaq: OMER) fell by over 39% during intraday trading today. This is why it happened.
- 10/01/2021
|
OMER Stock: Why Little-Known Omeros Is Absolutely Plunging Today
- Today, some rather unfortunate news has come to light regarding one of Omeros' prospective drugs, taking OMER stock 40% lower. The post OMER Stock: Why Little-Known Omeros Is Absolutely Plunging Today appeared first on InvestorPlace.
- 10/01/2021
|
Here's why Omeros Corp shares are down 40% on Friday morning
- The U.S. FDA notified Omeros Corporation (NASDAQ: OMER) that it identified deficiencies in the company's marketing application for Narsoplimab, Omeros disclosed in a press release this morning. Shares of the company tanked more than 40% on Friday.
- 10/01/2021
|
Here's Why Omeros Stock Is Tanking Today
- The narsoplimab program hasn't proceeded as swimmingly as investors thought.
- 10/01/2021
|
Do Options Traders Know Something About Omeros (OMER) Stock We Don't?
- Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.
- 10/01/2021
|
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA's ongoing review of the company's Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. FDA stated tha
- 10/01/2021
|
Why Omeros Stock Is Plummeting This Week
- The biotech stock was part of a larger Wall Street sell-off.
- 09/30/2021
|
Omeros: The Prize Is Nigh (Again)
- Omeros: The Prize Is Nigh (Again)
- 09/13/2021
|
Omeros Corporation's (OMER) CEO Greg Demopulos on Q2 2021 Results - Earnings Call Transcript
- Omeros Corporation's (OMER) CEO Greg Demopulos on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates
- Omeros (OMER) delivered earnings and revenue surprises of 20.00% and 11.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Omeros: Q2 Earnings Insights
- Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to ($0.46), which beat the estimate of ($0.57).
- 08/09/2021
|
Omeros: PDUFA Delay Presents An Opportunity
- Omeros has had its PDUFA delayed by three months. The reason is that the FDA needs additional time to review data it had asked for.
- 07/03/2021
|
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
- Omeros (OMER) announces initial results from a phase I study of OMS906.
- 06/10/2021
|
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced publication of the article “Selective inhibition of phosphodiesterase 7 enzymes reduces motivation fo
- 06/10/2021
|
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff Meacham, PhD, is scheduled for Tuesday, June 15, 2021 at 4:30 p.m. EDT. The presentation will be webcast. The live and archived webcasts can be accessed at https://investor.omeros.com/upcoming-events. The archived webcast
- 06/09/2021
|
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906. The ongoing trial
- 06/09/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 06/05/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Robert S.
- 06/01/2021
|
Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients
- Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.
- 05/31/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- New York, New York--(Newsfile Corp. - May 29, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 05/29/2021
|
Omeros's Narsoplimab Shows Encouraging Action In Critically Ill COVID-19 Patients
- Omeros Corporation (NASDAQ: OMER) has announced preliminary results from the second cohort (n=10) of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. The patients were part of the "second surge" of COVID-19 in Italy.
- 05/28/2021
|
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplim
- 05/28/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- New York, New York--(Newsfile Corp. - May 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 05/22/2021
|
Omeros' (OMER) BLA for Narsoplimab Gets Extended Review
- The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.
- 05/21/2021
|
Omeros's Narsoplimab US Application Review Pushed By 3 Months, Shares Drop
- Omeros Corporation (NASDAQ: OMER) has revealed that the FDA needs additional time to review narsoplimab marketing application for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The new target action date is October 17, compared to the earlier date of July 17.
- 05/20/2021
|
Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today reported that the U.S. Food and Drug Administration (FDA) will require additional time to review the Biologics
- 05/20/2021
|
Omeros Corp (OMER) CEO Gregory Demopulos on Q1 2021 Results - Earnings Call Transcript
- Omeros Corp (OMER) CEO Gregory Demopulos on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Omeros: Q1 Earnings Insights
- Shares of Omeros (NASDAQ:OMER) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 7.55% over the past year to ($0.57), which were in line with the estimate of ($0.57).
- 05/10/2021
|
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone, ple
- 05/05/2021
|
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). The absence of a specific HSCT-TMA diagnosis code has led to underreporting of diagnoses and inaccurate coding, which has complicated reporting of the incidence and outcomes of the dis
- 05/04/2021
|
Omeros: The Prize Is Nigh
- FDA action approving narsoplimab in treatment of HSCT-TMA in Omeros' upcoming PDUFA date has the potential to vault Omeros into multibagger territory overnight. Omeros' narsoplimab in treatment of severely ill COVID-19 patients presents an interesting opportunity.
- 04/18/2021
|
Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
- SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month. The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative. The goal of the trial is to screen rapidly, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality and avoi
- 03/23/2021
|
Omeros Corp (OMER) CEO Greg Demopulos on Q4 2020 Results - Earnings Call Transcript
- Omeros Corp (OMER) CEO Greg Demopulos on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
Omeros (OMER) Reports Q4 Loss, Misses Revenue Estimates
- Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2021
|
Recap: Omeros Q4 Earnings
- Shares of Omeros (NASDAQ:OMER) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 3.45% over the past year to ($0.60), which beat the estimate of ($0.64).
- 03/01/2021
|
Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and
- 03/01/2021
|
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Monday, March 1, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference c
- 02/25/2021
|
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
- Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/22/2021
|
Omeros: Multibagger On The Horizon
- Omeros' Biologics License Application (BLA) for orphan drug narsoplimab was accepted by FDA and was given priority review with FDA action date of July 17, 2021. This BLA is for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a rare, unmet, life-threatening disease.
- 02/10/2021
|
Omeros: On A Tear, More To Come
- Omeros has doubled since my last (10/20) bullish article. The company is still vastly undervalued with its current market cap of ~$1.3 billion.
- 02/10/2021
|
Omeros Hires Nadia Dac as Chief Commercial Officer
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial launch of narsoplimab, the company's mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor. A Biologics License Application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated
- 01/26/2021
|
Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The BLA has been granted Priority Review with an FDA action date of July 17, 2021 under the Prescription Drug User Fee Act (PDUFA). FDA also indicated in its filing letter that the
- 01/19/2021
|
Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference this year. The presentation is scheduled for Wednesday, January 13, 2021 at 10:50 a.m. EST. The presentation will be webcast. The live and archived webcasts can be accessed on the investor relations section of the company
- 01/11/2021
|
Omeros: A Ripening Fruit Ready To Pick
- Omeros: A Ripening Fruit Ready To Pick
- 12/09/2020
|
CMS Confirms Continued Separate Payment for Omeros' FDA-Approved OMIDRIA® in Ambulatory Surgery Centers
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros' cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. In its final rule directed to the Medicare outpatient prospective payment system (OPPS) and the ASC payment system for calendar year 2021, CMS confirmed that OMIDRIA qualifies for separate payment
- 12/03/2020
|
Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call Transcript
- Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 21)
Amicus Therapeutics, Inc. (...
- 10/22/2020
|
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
- Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
The week was a quiet...
- 10/18/2020
|
Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit
- Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the
- 10/16/2020
|
Omeros' COVID-19 Opportunity And Challenges
- Omeros' old story, with its heavy reliance on OMIDRIA revenues, is drifting away. Omeros' initial success in treating COVID-19 presents intriguing possibilities.
- 08/17/2020
|
Here's Why Omeros Fell Over 13% Today
- Shares of Omeros (NASDAQ: OMER) fell as much as 13.3% today after the company announced the pricing of a public offering of common stock and more details about a debt offering. The biopharma will offer up to 7.9 million shares of common stock at $14.50 apiece, which would haul in gross proceeds of roughly $115 million. Investors are displeased that the offering price is far below the $20-plus mark shares soared to after the company reported encouraging results from a six-patient study in COVID-19-associated acute respiratory distress syndrome (ARDS).
- 08/12/2020
|
Omeros Announces Pricing of Public Offerings
- Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common stock (the "Shares") at a public offering price of $14.50 per Share for proceeds of approximately $100,050,000, prior to the deduction of underwriting discounts and commissions and estimated offering expenses payable by Omeros (the "Equity Offering"), and $210,000,000 aggregate principal amount of 5.25% convertible senior notes due 2026 (the "2026 Convertible Notes" and such offering, the "Notes Offering"). In addition, Omeros has granted to the underwriters of the Equity Offering a 30-day option to purchase up to an additional 1,035,000 Shares and to the underwriters of the Notes Offering a 30-day option, solely to cover over-allotments, to purchase up to an additional $31,500,000 aggregate principal amount of 2026 Convertible Notes. The Equity Offering and the Notes Offering are each expected to close on August 14, 2020, subject to customary closing conditions. Neither offering is contingent on the completion of the other offering.
- 08/12/2020
|
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
- Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) * Allovir Inc (NASDAQ: ALVR) * BioLife Solutions Inc (NASDAQ: BLFS) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) (reacted to second-quarter results) * CymaBay Therapeutics Inc (NASDAQ: CBAY) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Fennec Pharmaceuticals Inc (NASDAQ: FENC) * Fulgent Genetics Inc (NASDAQ: FLGT) * Harvard Bioscience, Inc. (NASDAQ: HBIO) * Inari Medical Inc (NASDAQ: NARI) * Kura Oncology Inc (NASDAQ: KURA) * Omeros Corporation (NASDAQ: OMER) (announced positive results for the study of its lead asset in COVID-19) * Pacira Biosciences Inc (NASDAQ: PCRX) * RedHill Biopharma Ltd (NASDAQ: RDHL) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * Seres Therapeutics Inc (NASDAQ: MCRB) (reacted to positive late-stage clinical readout) * Silk Road Medical Inc (NASDAQ: SILK) * Sorrento Therapeutics Inc (NASDAQ: SRNE) * Trevena Inc (NASDAQ: TRVN) (announced FDA nod for pain drug) * Unity Biotechnology Inc (NASDAQ: UBX) * Vaxcyte Inc (NASDAQ: PCVX)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 10) * Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) (went public Friday) * Freeline Therapeutics Holdings plc ADS (NASDAQ: FRLN) (went public Friday) * Lantern Pharma Inc. (NASDAQ: LTRN) * Nkarta Inc (NASDAQ: NKTX) * Recro Pharma Inc (NASDAQ: REPH) (reacted to second-quarter results)Stocks In Focus Equillium Announces Positive Interim Data For Lead Drug, Requests Pre-IND Meeting For COVID-19 Study Equillium Inc (NASDAQ: EQ) announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease. Across the first two dose cohorts, itolizumab has been generally well-tolerated to date, and five of seven patients achieved a complete response by day 29, the company said.Additionally, Equillium said it has submitted a request to the FDA for a pre-IND meeting to review its proposal to initiate a global randomized controlled clinical trial to study itolizumab in hospitalized patients with COVID-19.The stock was trading 21.29% higher premarket Tuesday at $12.19. Clearside's IND Application Approved For Wet AMD Study Clearside Biomedical Inc (NASDAQ: CLSD) said the FDA has accepted its IND application for CLS-AX, enabling initiation of a Phase 1/2a clinical trial of CLS-AX in neovascular age-related macular degeneration patients by the end of 2020.The dose-escalation study will assess the safety and tolerability of single doses of CLS-AX administered through suprachoroidal injection following two or more prior treatments with an intravitreal anti-VEGF agent, according to the company. Separately, the company announced second-quarter results, reporting an increase in license revenue from $45,000 in 2019 to $354,000 in 2020. The net loss per share narrowed from 15 cents to 13 cents, but was wider than the 12-cent-per-share loss expected by analysts.The stock was up 7.26% at $1.92 premarket Tuesday.Innate Pharma Receives French Government Funding For COVID-19 Research Innate Pharma SA (NASDAQ: IPHA) said it has received 6.8 million euros ($8 million) in funding from the French government to support its COVID-19 R&D activities.The company said it expects the funding to help cover the development of the COVID-19 activities it began in March 2020, including the EXPLORE COVID-19 translational research study and its two Phase 2 clinical trials, FORCE and ImmunONCOVID-20.Fennec Handed Complete Response Letter For Drug To Treat Chemotherapy-Induced Ototoxicity Fennec Pharma said it received a complete response letter Monday from the FDA regarding its NDA for Pedmark, a unique formulation of sodium thiosulfate, for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic solid tumors.The stock was plunging 28.42% premarket to $7.28.See also: The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earning Catalyst's Firdapse Flunks Late-Stage Study In Neuromuscular Disease Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) said the top-line results from its Phase 3 study for Firdapse in anti-MuSK antibody positive myasthenia gravis patients did not replicate the robust positive results that were observed in the 2017 proof-of-concept study. The study did not meet the primary or secondary endpoints.The company also reported second-quarter results, showing a modest increase in revenue but a decline in EPS, which beat the consensus estimate by a penny.The stock was down 11.14% at $3.79 premarket. Ligand To Buy Pfenex For Up To $516M Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and Pfenex Inc (NYSE: PFNX) announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12 per share in cash or $438 million in equity value on a fully diluted basis.View more earnings on IBBAdditionally, Ligand will pay $2 per share or $78 million as a contingent value right in the event a predefined regulatory milestone is achieved by Dec. 31, 2021, for a total transaction value of up to $516 million. The transaction is expected to close in the fourth quarter.In premarket trading, Pfenex shares were jumping 63.45% to $12.52.Mesoblast Slumps As FDA Raises Questions Over Stem Cell Efficacy In Graft-Versus-Host Disease Shares of stem cell therapy company Mesoblast limited (NASDAQ: MESO) moved to the downside after FDA staffers expressed doubts over the adequacy of evidence for the efficacy of the company's remestemcel-L for treating acute graft-versus-host disease in children.The comments came in a briefing document released ahead of an Adcom meeting. The FDA's Oncologic Drugs Advisory Committee is scheduled to meet Thursday to discuss the BLA submitted by the company.The stock was down 25.66% at $12.95 premarket Tuesday.Inovio To Commence Late-Stage Coronavirus Vaccine Study In September, Q2 Results Trail Estimates Inovio Pharmaceuticals Inc (NASDAQ: INO) said it looks forward to starting a Phase 2/3 coronavirus vaccine study in the U.S. in September.The company reported second-quarter revenue of $267,187 in 2020 compared to $135,673 in 2019. The loss per share widened from 30 cents to 83 cents. Analysts estimated a loss of 17 cents per share on revenue of $2.61 million.The stock was down 11.01% at $16.90 premarket Tuesday. Earnings ICU Medical Inc's (NASDAQ: ICUI) second-quarter revenue fell from $312.3 million in 2019 to $303.4 million, and adjusted EPS fell from $1.99 to $1.65. The results, however, exceeded expectations.Separately, the company announced a long-term agreement with Grifols SA - ADR ADR Class B (NASDAQ: GRFS) to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% sodium chloride injections in the U.S. Omeros said its second-quarter revenue fell from $26.8 million in 2019 to $13.5 million in 2020, with the downside blamed on the postponement of cataract procedures by ASCs and hospitals due to COVID-19.The net loss per share narrowed from 61 cents to 29 cents. The revenue missed estimates and the net loss per share was wider than the consensus estimate.Separately, the company said it has commenced concurrent underwritten public offerings of $125 million shares of its common stock and $200 million in an aggregate principal amount of convertible senior notes due 2026.The stock was down 7.83% at $19.65 premarket Tuesday.Offerings PDS Biotechnology Corp (NASDAQ: PDSB) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by the company.The stock was down 20.92% at $3.10 premarket Tuesday.On The Radar PDUFA Dates The FDA's decision on label expansion for Roche Holdings AG's Basel ADR Common Stock (OTC: RHHBY) Xolair for the treatment of nasal polyps could arrive, as the company is 10 months out from the submission of the sBLA.Earnings * BioNTech SE - ADR (NASDAQ: BNTX) (before the market open) * STRATA Skin Sciences Inc (NASDAQ: SSKN) (before the market open) * Surface Oncology Inc (NASDAQ: SURF) (before the market open) * Prevail Therapeutics Inc (NASDAQ: PRVL) (before the market open) * Generation Bio Co (NASDAQ: GBIO) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Affimed NV (NASDAQ: AFMD) (before the market open) * Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open) * Gamida Cell Ltd (NASDAQ: GMDA) (before the market open) * 10X Genomics Inc (NASDAQ: TXG) (after the market close) * Agile Therapeutics Inc (NASDAQ: AGRX) (after the market close) * Aethlon Medical, Inc. (NASDAQ: AEMD) (after the market close) * T2 Biosystems Inc (NASDAQ: TTOO) (after the market close) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the market close) * DiaMedica Therapeutics Inc (NASDAQ: DMAC) (after the market close) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the market close) * Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) (after the market close) * Shockwave Medical Inc (NASDAQ: SWAV) (after the market close) * RA Medical Systems Inc (NYSE: RMED) (after the market close) * Inari Medical (after the market close)Related Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates See more from Benzinga * The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs * The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/11/2020
|
Omeros (OMER) Reports Q2 Loss, Lags Revenue Estimates
- Omeros (OMER) delivered earnings and revenue surprises of 11.11% and -25.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2020
|
Omeros : Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes | MarketScreener
|
Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
- Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced that it has commenced concurrent underwritten public offerings of $125,000,000 of shares of its common stock (the "Shares") and $200,000,000 aggregate principal amount of convertible senior notes due 2026 (the "2026 Convertible Notes"). In addition, Omeros has granted to the underwriters of the offering of Shares (the "Equity Offering") a 30-day option to purchase up to an additional $18,750,000 of Shares and to the underwriters of the offering of 2026 Convertible Notes (the "Notes Offering") a 30-day option, solely to cover over-allotments, to purchase up to an additional $30,000,000 aggregate principal amount of 2026 Convertible Notes. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offerings may be completed or as to the actual size or terms of the offerings. Neither offering is contingent on the completion of the other offering.
- 08/10/2020
|
Omeros Corporation Reports Second Quarter 2020 Financial Results
- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2020, which include:
- 08/10/2020
|
Dow Jones Leads, Nasdaq Lags As Market Weighs Trump Orders, China Tensions
- The Dow Jones Industrial Average hit new session highs midday while the Nasdaq lagged, amid heightened U.S.-China tensions.
- 08/10/2020
|
Omeros Rallies On COVID-19 Study Results: What You Should Know
- Omeros Corporation (NASDAQ: OMER) shares were galloping higher Monday after the biopharma announced results from a compassionate use study of its lead investigational human monoclonal antibody.What Happened: Seattle-based Omeros said its narsoplimab, when administered to six COVID-19 patients with Acute Respiratory Distress Syndrome who initially required mechanical ventilation, led to recovery, survival and discharge from the hospital.Mannan-binding lectin-associated serine protease-2, or MASP-2, binds the nucleocapsid protein of SARS-CoV-2 -- the virus responsible for COVID-19 -- resulting in complement activation and lung injury.Narsoplimab targets MASP-2, alleviating symptoms of COVID-19, including ARDS and thrombotic events, according to Omeros. Narsoplimab is being evaluated as a treatment option for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or HSCT-TMA.Rolling BLA submission is underway for the indication, Omeros said.The study of narsoplimab in COVID-19 was initiated following a request from treating physicians at the Papa Giovanni XXIII Hospital in Bergamo, Italy, the company said.The uniformly successful outcomes of the study are impressive, Alessandro Rambaldi, head of the department of hematology and oncology at Papa Giovanni, said in a statement. Rambaldi also served as the lead investigator for the HSCT-TMA trial. "Also of importance in this terribly sick population studied, the drug was well-tolerated, showing no adverse effects," Rambaldi said. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.What's Next: Omeros said a manuscript detailing the results of the study has been accepted for publication in the peer-reviewed journal Immunobiology.OMER Price Action: At last check, Omeros shares were surging higher by 49.89% to $21.18. Related Links:The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earning Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates See more from Benzinga * Seres Therapeutics Skyrockets On Positive Pivotal Study Results For Microbiome Therapeutic * Why BofA Has The Street's Highest Nvidia Price Target Ahead Of The Q2 Print * Why iPhone 12 Will Be Another 'Defining Chapter' In Apple's Growth Story(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/10/2020
|
ROCE Insights For Omeros
- Omeros (NASDAQ: OMER) reported Q1 sales of $23.54 million. Earnings fell to a loss of $23.68 million, resulting in a 0.12% decrease from last quarter. Omeros collected $33.42 million in revenue during Q4, but reported earnings showed a $23.71 million loss.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q1, Omeros posted an ROCE of 0.18%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on OMERReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.In Omeros's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.Q1 Earnings Recap Omeros reported Q1 earnings per share at $-0.53/share, which did not meet analyst predictions of $-0.34/share.See more from Benzinga * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/10/2020
|
Omeros Reports Coronavirus Treatment Success; Stock Soars
- Small Omeros on Monday reported success with a test of its corononavirus treatment, saying it helped the recovery of six patients severely ill with Covid-19.
- 08/10/2020
|
Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome
- Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe and life-threatening symptom of COVID-19. All patients initially required mechanical ventilation, and all recovered and survived with narsoplimab treatment. A manuscript detailing the results of the study has been accepted for publication in the peer-reviewed journal Immunobiology. A pre-publication copy of the manuscript can be accessed at https://www.sciencedirect.com/science/article/pii/S0171298520304459.
- 08/10/2020
|
Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome
- Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monocl
- 08/10/2020
|
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
- Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/06/2020
|
Could This Obscure Biotech Stock Make You a Fortune?
- Two major catalysts on the horizon could send Omeros' stock soaring. What should investors think?
- 07/26/2020
|
The Play On Omeros
- Today, we revisit Omeros. The company has two potential catalysts on the near term horizon and the stock is a good covered call candidate.
- 07/17/2020
|
Omeros'(NASDAQ:OMER) Share Price Is Down 35% Over The Past Three Years.
- Many investors define successful investing as beating the market average over the long term. But its virtually certain...
- 07/15/2020
|
Hedge Funds Are Buying Omeros Corporation (OMER)
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- 06/24/2020
|
American Kidney Fund Announces Corporate Membership Program for Institutional Partners Supporting Fight Against Kidney Disease | | IT Business Net
- ROCKVILLE, MD / ACCESSWIRE / June 22, 2020 / The American Kidney Fund (AKF) today announced a new corporate membership program open to institutional partners that support AKF's core mission of fi
- 06/22/2020
|
The Global Cataract Surgery Devices Market is expected to grow from USD 5,460.48 Million in 2019 to USD 8,206.33 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.02%
- Market Segmentation & Coverage: This research report categorizes the Cataract Surgery Devices to forecast the revenues and analyze the trends in each of the following sub-markets:
- 06/20/2020
|
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress
- Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 25th Congress of the European Hematology Association (EHA). The EHA oral presentation, entitled Narsoplimab (OMS721) for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy was delivered by Alessandro Rambaldi, MD, Professor, Department of Oncology and Hematology-Oncology at the University of Milan and Head of the Hematology and Bone Marrow Transplant Unit at ASST Papa Giovanni XXIII in Bergamo, Italy.
- 06/12/2020
|
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress
- Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell tra
- 06/12/2020
|
Omeros’ Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress
- Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the virtual edition of the 25th annual European Hematology Association Congress.
- 06/11/2020
|
Edited Transcript of OMER earnings conference call or presentation 11-May-20 8:30pm GMT
- Q1 2020 Omeros Corp Earnings Call
- 06/08/2020
|
Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75
- On Tuesday, Omeros received a positive adjustment to its Relative Strength (RS) Rating, from 67 to 75. Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating north of 80 as they launch their largest runs. See if Omeros can continue to show renewed price strength and clear that threshold.
- 05/26/2020
|
Eyewear Market to Hit USD 178.95 Billion by 2026; COVID-19 Scare to Propel the Demand Exponentially Owing to Deteriorating Eye Health: Fortune Business Insights™
- The global eyewear market size is expected to reach USD 178.95 Billion by 2026; owing to increasing cases of deteriorating eye health and trendsetting launch of
- 05/22/2020
|
Consonance Capital Management LP Buys Akebia Therapeutics Inc, Sarepta Therapeutics Inc, ...
|
Omeros: Some Concerns Remain... As Do Opportunities
- Today, we circle back on Omeros whose two main assets are Omidria and OMS721. The company's quarterly report had some Covid19 impacts and two potential large ca
- 05/14/2020
|
Omeros To Present Narsoplimab Pivotal Trial Data At European Hematology Association Annual Congress Jun. 11-14
|
Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress
- Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2020. This year the congress will be held virtually.
- 05/14/2020
|
Edited Transcript of OMER earnings conference call or presentation 11-May-20 8:30pm GMT
- Q1 2020 Omeros Corp Earnings Call
- 05/12/2020
|
Omeros (OMER) Q1 2020 Earnings Call Transcript
- All forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially. Please refer to the special note regarding forward-looking statements and the risk factors section in the company's quarterly report on Form 10-Q, which was filed today with the SEC, and the risk factors section of the company's 2019 annual report on Form 10-K for a discussion of these risks and uncertainties. Greg Demopulos, chairman and CEO of Omeros, will take you through a corporate update, and then Mike Jacobsen, our chief accounting officer, will provide an overview of our first-quarter financial results.
- 05/12/2020
|
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2020 Results - Earnings Call Transcript
- Omeros Corporation (NASDAQ:OMER) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Jennifer Williams – Investor Relations Greg Demop
- 05/12/2020
|
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
- Omeros (OMER) delivered earnings and revenue surprises of -2.50% and -23.88%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2020
|
Omeros Q1 EPS $(0.530) Misses $(0.340) Estimate, Sales $23.537M Miss $30.270M Estimate
|
Omeros Corporation Reports First Quarter 2020 Financial Results
- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2020, which include:
- 05/11/2020
|
Omeros Corporation Reports First Quarter 2020 Financial Results
- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecul
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Should You Buy Omeros (OMER) Ahead of Earnings?
- Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/08/2020
|
Should You Buy Omeros (OMER) Ahead of Earnings?
|
Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020
- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2020, on Monday, May 11, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
- 05/05/2020
|
Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020
- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2020
- 05/05/2020
|
InMode (INMD) to Post Q1 Earnings: What's in the Offing?
- InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.
- 05/01/2020
|
InMode (INMD) to Post Q1 Earnings: What's in the Offing?
- InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.
- 05/01/2020
|
Wedbush Weighs in on Omeros Co.'s Q1 2020 Earnings (NASDAQ:OMER)
- Omeros Co. (NASDAQ:OMER) – Research analysts at Wedbush increased their Q1 2020 EPS estimates for shares of Omeros in a research note issued on Monday, April 27th. Wedbush analyst L. Moussatos now expects that the biopharmaceutical company will post earnings per share of ($0.36) for the quarter, up from their previous forecast of ($0.41). Wedbush […]
- 05/01/2020
|
Wedbush Sticks to Their Hold Rating for Omeros (OMER)
- In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Omeros (OMER), with a price target of $17.00. The company's shares
- 04/27/2020
|
Wedbush Sticks to Their Hold Rating for Omeros (OMER)
- In a report released today,
Liana Moussatos
from Wedbush reiterated a
Hold
rating on Omeros (
OMER
–
Research Report
), with a price target of
$17.00
. The company’s shares closed last Monday at $16.34.
According to
TipRanks.com
, Moussatos is curren
- 04/27/2020
|
Nuveen Asset Management LLC Has $2.82 Million Stake in Omeros Co. (NASDAQ:OMER)
- Nuveen Asset Management LLC decreased its position in Omeros Co. (NASDAQ:OMER) by 2.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 199,819 shares of the biopharmaceutical company’s stock after selling 4,971 shares during the period. Nuveen Asset Management LLC owned about 0.37% of Omeros worth $2,815,000 […]
- 04/27/2020
|
Omeros (NASDAQ:OMER) Stock Rating Upgraded by BidaskClub
- Omeros (NASDAQ:OMER) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, BidAskClub reports. Several other analysts also recently commented on OMER. Wedbush restated a “hold” rating and set a $22.00 target price (up from $18.00) on shares of Omeros in a […]
- 04/25/2020
|
Omeros Clears Key Benchmark, Hitting 80-Plus RS Rating
|
Bank of America Corp DE Decreases Position in Omeros Co. (NASDAQ:OMER)
- Bank of America Corp DE reduced its position in shares of Omeros Co. (NASDAQ:OMER) by 10.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 80,768 shares of the biopharmaceutical company’s stock after selling 9,405 shares during the period. Bank of […]
- 04/23/2020
|
Bank of New York Mellon Corp Increases Position in Omeros Co. (NASDAQ:OMER)
- Bank of New York Mellon Corp boosted its holdings in shares of Omeros Co. (NASDAQ:OMER) by 3.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 210,880 shares of the biopharmaceutical company’s stock after purchasing an additional 6,100 shares during the quarter. Bank of […]
- 04/19/2020
|
Advaxis (NASDAQ:ADXS) versus Omeros (NASDAQ:OMER) Head-To-Head Review
- Omeros (NASDAQ:OMER) and Advaxis (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Insider and Institutional Ownership 51.2% of Omeros shares are owned by institutional investors. Comparatively, 10.6% of Advaxis […]
- 04/19/2020
|
Nwam LLC Has $381,000 Stock Position in Omeros Co. (NASDAQ:OMER)
- Nwam LLC reduced its position in shares of Omeros Co. (NASDAQ:OMER) by 10.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,470 shares of the biopharmaceutical company’s stock after selling 3,500 shares during the period. Nwam LLC […]
- 04/18/2020
|
Zacks: Brokerages Anticipate Omeros Co. (NASDAQ:OMER) to Announce -$0.43 Earnings Per Share
- Brokerages predict that Omeros Co. (NASDAQ:OMER) will report earnings per share of ($0.43) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Omeros’ earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.44). Omeros reported earnings per share of ($0.38) in the same quarter last year, which would suggest […]
- 04/13/2020
|
Zacks: Brokerages Anticipate Omeros Co. (NASDAQ:OMER) Will Announce Quarterly Sales of $30.92 Million
- Equities research analysts predict that Omeros Co. (NASDAQ:OMER) will report sales of $30.92 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Omeros’ earnings. The lowest sales estimate is $27.84 million and the highest is $34.00 million. Omeros posted sales of $21.78 million during the same quarter last […]
- 04/12/2020
|
Cypress Capital Group Has $455,000 Stake in Omeros Co. (NASDAQ:OMER)
- Cypress Capital Group increased its position in shares of Omeros Co. (NASDAQ:OMER) by 13.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 34,000 shares of the biopharmaceutical company’s stock after buying an additional 4,000 shares during the quarter. Cypress Capital Group owned 0.06% […]
- 04/09/2020
|
Brokerages Set Omeros Co. (NASDAQ:OMER) PT at $23.80
- Omeros Co. (NASDAQ:OMER) has received an average recommendation of “Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 12 month […]
- 04/08/2020
|
Baird Financial Group Inc. Takes Position in Omeros Co. (NASDAQ:OMER)
- Baird Financial Group Inc. purchased a new stake in shares of Omeros Co. (NASDAQ:OMER) during the 4th quarter, Holdings Channel.com reports. The fund purchased 12,200 shares of the biopharmaceutical company’s stock, valued at approximately $172,000. Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. California State […]
- 04/08/2020
|
Omeros Clears Technical Benchmark, Hitting 80-Plus RS Rating
|
Omeros Corporation: The Thesis Was Playing Out Before COVID-19 Hit
- We recommended Omeros on July 15 of last year when the stock was trading at $14.69/share. The stock spiked to almost $20/share on March 3 when great narsoplimab
- 03/31/2020
|
Omeros (NASDAQ:OMER) Upgraded to Buy by Zacks Investment Research
- Omeros (NASDAQ:OMER) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The brokerage currently has a $12.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 5.26% from the company’s previous […]
- 03/31/2020
|
19,300 Shares in Omeros Co. (NASDAQ:OMER) Bought by Alberta Investment Management Corp
- Alberta Investment Management Corp purchased a new position in shares of Omeros Co. (NASDAQ:OMER) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 19,300 shares of the biopharmaceutical company’s stock, valued at approximately $272,000. Other institutional investors and hedge funds have also […]
- 03/30/2020
|
Credit Suisse AG Increases Stock Holdings in Omeros Co. (NASDAQ:OMER)
- Credit Suisse AG raised its stake in Omeros Co. (NASDAQ:OMER) by 5.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 213,986 shares of the biopharmaceutical company’s stock after acquiring an additional 11,359 shares during the period. Credit Suisse AG’s holdings in Omeros were worth $3,015,000 as of its most recent SEC filing. A number […]
- 03/25/2020
|
Omeros (NASDAQ:OMER) Upgraded by Zacks Investment Research to Buy
- Omeros (NASDAQ:OMER) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The brokerage currently has a $12.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 8.21% from […]
- 03/25/2020
|
Omeros' Tumultuous March
- Omeros closed out Q4 2019 with an excellent earnings report. The company's Q4 earnings report showed its lead therapy, Narsoplimab, cruising to a near landing o
- 03/20/2020
|
$30.92 Million in Sales Expected for Omeros Co. (NASDAQ:OMER) This Quarter
- Wall Street brokerages expect that Omeros Co. (NASDAQ:OMER) will report $30.92 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Omeros’ earnings. The lowest sales estimate is $27.84 million and the highest is $34.00 million. Omeros reported sales of $21.78 million during the same quarter last year, […]
- 03/20/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) …
- 03/17/2020
|
Brokerages Set Omeros Co. (NASDAQ:OMER) Price Target at $26.75
- Shares of Omeros Co. (NASDAQ:OMER) have been given an average recommendation of “Hold” by the eight brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average […]
- 03/14/2020
|
Omeros (NASDAQ:OMER) Stock Rating Upgraded by ValuEngine
- Omeros (NASDAQ:OMER) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Tuesday, ValuEngine reports. A number of other equities research analysts have also weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Omeros in a […]
- 03/12/2020
|
Edited Transcript of OMER earnings conference call or presentation 2-Mar-20 9:30pm GMT
- Q4 2019 Omeros Corp Earnings Call
- 03/11/2020
|
Edited Transcript of OMER earnings conference call or presentation 2-Mar-20 9:30pm GMT
- Q4 2019 Omeros Corp Earnings Call
- 03/11/2020
|
Capital Impact Advisors LLC Boosts Position in Omeros Co. (NASDAQ:OMER)
- Capital Impact Advisors LLC increased its holdings in shares of Omeros Co. (NASDAQ:OMER) by 23.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 130,187 shares of the biopharmaceutical company’s stock after purchasing an additional 24,372 shares during the quarter. […]
- 03/11/2020
|
Cantor Fitzgerald Research Analysts Increase Earnings Estimates for Omeros Co. (NASDAQ:OMER)
- Omeros Co. (NASDAQ:OMER) – Research analysts at Cantor Fitzgerald upped their FY2020 earnings per share estimates for shares of Omeros in a research note issued to investors on Thursday, March 5th. Cantor Fitzgerald analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings of ($1.09) per share for the year, up from their […]
- 03/09/2020
|
Wedbush Reiterates Hold Rating for Omeros (NASDAQ:OMER)
- Wedbush restated their hold rating on shares of Omeros (NASDAQ:OMER) in a research report sent to investors on Wednesday, The Fly reports. Wedbush currently has a $22.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $18.00. Wedbush also issued estimates for Omeros’ FY2024 earnings at $0.88 EPS. OMER has […]
- 03/08/2020
|
Analysts Set Expectations for Omeros Co.'s FY2024 Earnings (NASDAQ:OMER)
- Omeros Co. (NASDAQ:OMER) – Stock analysts at Wedbush issued their FY2024 EPS estimates for shares of Omeros in a research note issued to investors on Wednesday, March 4th. Wedbush analyst L. Moussatos anticipates that the biopharmaceutical company will earn $0.88 per share for the year. Wedbush currently has a “Hold” rating and a $22.00 target […]
- 03/08/2020
|
New York State Common Retirement Fund Sells 6,400 Shares of Omeros Co. (NASDAQ:OMER)
- New York State Common Retirement Fund decreased its stake in shares of Omeros Co. (NASDAQ:OMER) by 13.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,900 shares of the biopharmaceutical company’s stock after selling 6,400 shares during the period. New York State Common […]
- 03/07/2020
|
Chicago Equity Partners LLC Trims Stake in Omeros Co. (NASDAQ:OMER)
- Chicago Equity Partners LLC reduced its holdings in shares of Omeros Co. (NASDAQ:OMER) by 49.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,925 shares of the biopharmaceutical company’s stock after selling 34,700 shares during the period. Chicago Equity Partners LLC […]
- 03/06/2020
|
BidaskClub Upgrades Omeros (NASDAQ:OMER) to Hold
- Omeros (NASDAQ:OMER) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Friday, BidAskClub reports. OMER has been the subject of several other research reports. Maxim Group reissued a “buy” rating and set a $25.00 price target on shares of Omeros in a report […]
- 03/06/2020
|
Stocks Showing Market Leadership: Omeros Earns 93 RS Rating
|
Omeros Corporation Yearly Results Just Came Out: Here’s What Analysts Are Forecasting For Next Year
- Shareholders will be ecstatic, with their stake up 66% over the past week following Omeros Corporation's (NASDAQ:OMER...
- 03/05/2020
|
Omeros (OMER) Q4 2019 Earnings Call Transcript
- OMER earnings call for the period ending December 31, 2019.
- 03/05/2020
|
Wedbush Reiterates a Hold Rating on Omeros (OMER)
- Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros (OMER) today and set a price target of $22.00. The company's shares closed last Monday
- 03/04/2020
|
Wedbush Reiterates a Hold Rating on Omeros (OMER)
- Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros (OMER – Research Report) today and set a price target
- 03/04/2020
|
Omeros (OMER) Received its Third Buy in a Row
- After H.C. Wainwright and Cantor Fitzgerald gave Omeros (NASDAQ: OMER) a Buy rating last month, the company received another Buy, this time from Maxim
- 03/04/2020
|
Omeros (OMER) Received its Third Buy in a Row
- After H.C. Wainwright and Cantor Fitzgerald gave Omeros (NASDAQ:
OMER
) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst
Jason McCarthy
maintained a
Buy
rating on Omeros today and set a price target of
$2
- 03/04/2020
|
Company News for Mar 4, 2020
- Companies in the news are: SCON, OMER, QGEN, TLRY
- 03/04/2020
|
Company News for Mar 4, 2020
- Companies in the news are: SCON, OMER, QGEN, TLRY
- 03/04/2020
|
Ranpak Appoints Former Amazon Global Treasurer to Its Board of Directors
- Ranpak Holdings Corp. ("Ranpak") (NYSE: PACK), a leading provider of environmentally sustainable, systems-based, product protection solutions for e-commerce and industrial supply chains, today announced that on March 3, 2020, Kurt Zumwalt was appointed to the company’s board of directors, effective
- 03/04/2020
|
Omeros' (OMER) "Buy" Rating Reaffirmed at HC Wainwright
- HC Wainwright reiterated their buy rating on shares of Omeros (NASDAQ:OMER) in a research note released on Tuesday morning, TipRanks reports. The firm currently has a $34.00 price objective on the biopharmaceutical company’s stock. A number of other analysts have also weighed in on OMER. Maxim Group reiterated a buy rating and set a $25.00 […]
- 03/04/2020
|
85 Biggest Movers From Yesterday
- Gainers
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) shares climbed 69.7% to close at $7.45. Inovio Pharmaceuticals announced an accelerated timeline Tuesday for the development of...
- 03/04/2020
|
Company News for Mar 4, 2020
|
Mid-Afternoon Market Update: Dow Tumbles 800 Points; Superconductor Technologies Shares Spike Higher
- Toward the end of trading Tuesday, the Dow traded down 3.03% to 25893.26 while the NASDAQ fell 3.13% to 8,672.22. The S&P also fell, dropping 2.87% to 3,001.43. Coronavirus...
- 03/03/2020
|
Here's Why Omeros Corporation Stock Rose as Much as 46.5% Today
- The company reported full-year 2019 operating results and a separate update from the pipeline.
- 03/03/2020
|
Fly Intel: Wall Street's top stories at midday KSS;TGT;TLRY;V;H;HPQ;XRX;CVX;QGEN;TMO;OMER;WIFI;CRON;GSKY;PI
- Fly Intel: Wall Street's top stories at midday KSS TGT TLRY V H HPQ XRX CVX QGEN TMO OMER WIFI CRON GSKY PI
- 03/03/2020
|
Mid-Day Market Update: Dow Falls Over 200 Points; Fed Issues Emergency Interest Rate Cut
- Midway through trading Tuesday, the Dow traded down 0.77% to 26497.47 while the NASDAQ fell 0.37% to 8,919.22. The S&P also fell, dropping 0.49% to 3,075.01. Coronavirus cases...
- 03/03/2020
|
50 Stocks Moving In Tuesday's Mid-Day Session
- Gainers
Superconductor Technologies Inc. (NASDAQ: SCON) shares jumped 107.1% to $0.4079. Superconductor Technologies and Allied Integral United announced a merger agreement....
- 03/03/2020
|
Omeros shares are trading higher after the company reported Narsoplimab HSCT-TMA results surpassed the FDA-agreed efficacy threshold.
|
Mid-Morning Market Update: Markets Open Higher; Target Posts Mixed Q4 results
- Following the market opening Tuesday, the Dow traded up 0.27% to 26,774.19 while the NASDAQ rose 0.48% to 8,996.28. The S&P also rose, gaining 0.44% to 3,103.90. Coronavirus...
- 03/03/2020
|
TSLA, INO among premarket gainers
- Stealth BioTherapeutics (NASDAQ:MITO) +56% on Rare Pediatric Disease tag for elamipretide.GenMark Diagnostics (NASDAQ:GNMK) +28% as company ships ePlex RUO test kits for SARS-CoV-2 detection and Q4 re
- 03/03/2020
|
Omeros reports narsoplimab data and highlights from CMC meetings; shares up 15% premarket
- Omeros (NASDAQ:OMER) reports an update on clinical data from its pivotal trial of narsoplimab, a human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2) in the
- 03/03/2020
|
Analysts Offer Insights on Healthcare Companies: Amag Pharmaceuticals (AMAG) and Omeros (OMER)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amag Pharmaceuticals (AMAG) and Omeros (OMER) with bullish
- 03/03/2020
|
Analysts Offer Insights on Healthcare Companies: Amag Pharmaceuticals (NASDAQ: AMAG) and Omeros (NASDAQ: OMER)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amag Pharmaceuticals
- 03/03/2020
|
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
- 03/03/2020
|
40 Stocks Moving in Tuesday's Pre-Market Session
- Gainers
Superconductor Technologies Inc. (NASDAQ: SCON) shares rose 123.3% to $0.44 in pre-market trading. Superconductor Technologies and Allied Integral United announced a...
- 03/03/2020
|
Omeros Corporation (OMER) CEO Greg Demopulos on Q4 2019 Results - Earnings Call Transcript
- Omeros Corporation (NASDAQ:OMER) Q4 2019 Earnings Conference Call March 2, 2020 16:30 ET CompanyParticipants Jennifer Williams - IR, Cook Williams Communication
- 03/03/2020
|
Omeros (OMER) Reports Q4 Loss, Tops Revenue Estimates
- Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 03/02/2020
|
Omeros (OMER) Reports Q4 Loss, Tops Revenue Estimates
- Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 03/02/2020
|
15 Stocks Moving In Monday's After-Hours Session
- Gainers
Omeros (NASDAQ: OMER) shares are trading higher after the company reported Narsoplimab HSCT-TMA results surpassed the FDA-agreed efficacy threshold.
Fate Therapeutics...
- 03/02/2020
|
Omeros: 4Q Earnings Snapshot
- SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $29.2 million in its fourth quarter. On a per-share basis, the Seattle-based company said it had a loss of 58 cents. Losses, adjusted for non-recurring costs, came to 21 cents per share. The drug developer posted revenue of $33.4 million in the period. For the year, the company reported that its loss narrowed to $84.5 million, or $1.71 per share. Revenue was reported as $111.8 million. Omeros shares have fallen 11% since the beginning of the year. In the final minutes of trading on Monday, shares hit $12.59, a drop of 17% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OMER at https://www.zacks.com/ap/OMER
- 03/02/2020
|
Omeros: 4Q Earnings Snapshot
- SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $29.2 million in its fourth quarter. On a per-share basis, the Seattle-based company said it had a loss of 58 cents. Omeros shares have fallen 11% since the beginning of the year.
- 03/02/2020
|
Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and
- 03/02/2020
|
Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint. While an overview of preliminary data submitted to FDA was made public on December 4, 2019 in a press release from the company, all patients have now completed treatment and tr
- 03/02/2020
|
Omeros shares are trading higher after the company reported Narsoplimab HSCT-TMA results surpassed the FDA-agreed efficacy threshold.
|
The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
- Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved advantageous for some biotechs that disclosed plans to work on therapies or vaccines for countering the viral attack. The FDA approved Esperion Therapeutics Inc's (NASDAQ: ESPR ) LDL-cholesterol lowering combo therapy and Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN ) migraine drug . The following are key catalysts that could move biotech stocks in the unfolding week. Conferences Cowen 40th Annual Healthcare Conference: March 2-4 in Boston, Massachusetts Related Link: Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug Earnings Monday Albireo Pharma Inc (NASDAQ: ALBO ) (before the market open) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) (before the market open) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (before the market open) Seres Therapeutics Inc (NASDAQ: MCRB ) (before the market open) Urogen Pharma Ltd (NASDAQ: URGN ) …
- 02/29/2020
|
Omeros (OMER) Scheduled to Post Quarterly Earnings on Monday
- Omeros (NASDAQ:OMER) is scheduled to be issuing its Q4 2019 quarterly earnings data after the market closes on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link. Shares of OMER […]
- 02/29/2020
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Feb. 27)
Global Cord Blood Corp (...
- 02/28/2020
|
Stocks That Hit 52-Week Lows On Friday
|
Stocks That Hit 52-Week Lows On Thursday
|
$31.38 Million in Sales Expected for Omeros Co. (NASDAQ:OMER) This Quarter
- Wall Street brokerages predict that Omeros Co. (NASDAQ:OMER) will announce $31.38 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Omeros’ earnings. The highest sales estimate is $36.30 million and the lowest is $26.46 million. Omeros posted sales of $22.02 million in the same quarter last year, […]
- 02/26/2020
|
Omeros (NASDAQ:OMER) Upgraded to Sell at BidaskClub
- Omeros (NASDAQ:OMER) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Tuesday, BidAskClub reports. A number of other equities research analysts have also weighed in on OMER. Zacks Investment Research lowered Omeros from a “buy” rating to a “hold” rating in a […]
- 02/25/2020
|
Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conferen
- 02/24/2020
|
Omeros Co. (NASDAQ:OMER) Given Average Rating of "Hold" by Brokerages
- Shares of Omeros Co. (NASDAQ:OMER) have earned an average recommendation of “Hold” from the eight analysts that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year target […]
- 02/20/2020
|
Should You Worry About Omeros Corporation’s (NASDAQ:OMER) CEO Pay?
- In 1994 Greg Demopulos was appointed CEO of Omeros Corporation (NASDAQ:OMER). First, this article will compare CEO...
- 02/18/2020
|
Is Omeros Corporation's (NASDAQ:OMER) CEO Salary Justified?
- Gregory Demopulos became the CEO of Omeros Corporation (NASDAQ:OMER) in 1994. This report will, first, examine the CEO...
- 02/11/2020
|
Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors
- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.com, Inc., to Omeros’ Board of Directors. He will also serve in a consulting role at Omeros. Mr. Zumwalt brings significant expertise in developing comprehensive business relationships with major banks and financial institutions.
- 02/11/2020
|
Omeros: 2 Major Catalysts On The Horizon
- Omeros Corporation has had positive news regarding its late-stage candidate OMS721 counterbalanced by concerns that its product Omidria may lose its separate re
- 02/10/2020
|
-$0.33 EPS Expected for Omeros Co. (NASDAQ:OMER) This Quarter
- Equities research analysts expect Omeros Co. (NASDAQ:OMER) to report ($0.33) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Omeros’ earnings, with estimates ranging from ($0.41) to ($0.24). Omeros posted earnings of ($0.38) per share in the same quarter last year, which would suggest a positive […]
- 02/09/2020
|
Most Heavily Shorted Stocks - February 2020
- This article presents a list of stocks with the highest short interest as a percentage of shares outstanding. The most heavily shorted stocks here are generally
- 02/06/2020
|
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) ( announced a deal to buy cell and gene therapy CDMO MasTherCell and forecast-beating second quarter results) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Molecular Templates Inc (NASDAQ: MTEM ) Orgenesis Inc (NASDAQ: ORGS ) (announced sale of subsidiary MasTherCell to Catalent) Profound Medical Corp (NASDAQ: PROF ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) Theravance Biopharma Inc (NASDAQ: TBPH ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 3.) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Avanos Medical Inc (NYSE: AVNS ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) (moved along with China pharmaceutical stocks due to coronavirus) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) I-Mab (NASDAQ: IMAB ) (went public in mid-January) Intec Pharma Ltd (NASDAQ: NTEC ) TapImmune Inc. (NASDAQ: MRKR ) Omeros Corporation (NASDAQ: OMER ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 …
- 02/04/2020
|
Omeros (NASDAQ:OMER) Downgraded by BidaskClub
- Omeros (NASDAQ:OMER) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Tuesday, BidAskClub reports. Several other equities analysts have also weighed in on the stock. Wedbush reiterated a “hold” rating and set a $18.00 price objective on shares of Omeros in a […]
- 02/04/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (OMER). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 02/03/2020
|
Stocks That Hit 52-Week Lows On Monday
- Monday's morning session saw 187 companies set new 52-week lows.
Interesting Highlights:
Xperi (NASDAQ: XPER) was the biggest company on a market cap basis to set a...
- 02/03/2020
|
Forensic Value Stock Analysis: The Highest Positive And Negative Scoring Stocks For February
- The new February selections for both Positive and Negative Forensic Value stocks released in alternating months with the Piotroski-Graham Value selections. 11 P
- 02/03/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros ...
|
Stocks That Hit 52-Week Lows On Friday
- Friday's morning session saw 167 companies set new 52-week lows.
Facts of Interest:
The largest company in terms of market cap to set a new 52-week low was Xperi (...
- 01/31/2020
|
Omeros (NASDAQ:OMER) and Johnson & Johnson (NASDAQ:JNJ) Financial Contrast
- Omeros (NASDAQ:OMER) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Analyst Recommendations This is a breakdown of recent ratings and recommmendations for Omeros and Johnson & […]
- 01/30/2020
|
Obsessive-Compulsive Disorder Therapeutic Landscape & Pipeline Review (2020, H1)
- The "Obsessive-Compulsive Disorder - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
- 01/24/2020
|
Obsessive-Compulsive Disorder - Pipeline Review, H1 2020
- Dublin, Jan. 24, 2020 -- The "Obsessive-Compulsive Disorder - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.This.
- 01/24/2020
|
Omeros seeks accelerated approval from FDA for new drug
- Seattle biotech company Omeros Corp. is seeking accelerated approval from the Federal Drug Administration for its drug that aims to fight a life-threatening disorder that can develop after receiving a stem cell transplant. Last month, Seattle Genetics received accelerated approval for one of its new drugs from the FDA, several months in advance of when approval was expected. Omeros seeks the same designation this year.
- 01/23/2020
|
Omeros (NASDAQ:OMER) Upgraded to "Sell" by BidaskClub
- BidaskClub upgraded shares of Omeros (NASDAQ:OMER) from a strong sell rating to a sell rating in a research note released on Friday, BidAskClub reports. A number of other equities analysts have also weighed in on OMER. Needham & Company LLC reissued a hold rating on shares of Omeros in a research report on Wednesday, December […]
- 01/21/2020
|
Monday’s Midday Movers: Omeros (OMER), Goodrich Petroleum (GDP), Karyopharm Therapeutics (KPTI), Ballard Power Systems (BLDP), Heron Therapeutics (HRTX)
- So far Monday, January 20, NASDAQ is down -3.65% and the S&P is up 0.25%. Let’s take a look at
- 01/20/2020
|
Sunday’s Midday Stock Update: Omeros (OMER), Goodrich Petroleum (GDP), Karyopharm Therapeutics (KPTI), Ballard Power Systems (BLDP), Heron Therapeutics (HRTX)
- So far Sunday, January 19, NASDAQ is down -3.65% and the S&P is up 0.25%. Let’s take a look at
- 01/19/2020
|
Saturday’s Midday Movers: Omeros (OMER), Goodrich Petroleum (GDP), Karyopharm Therapeutics (KPTI), Ballard Power Systems (BLDP), Heron Therapeutics (HRTX)
- So far Saturday, January 18, NASDAQ is down -3.65% and the S&P is up 0.25%. Here are this morning’s most
- 01/18/2020
|
What Kind Of Shareholder Owns Most Omeros Corporation (NASDAQ:OMER) Stock?
- A look at the shareholders of Omeros Corporation (NASDAQ:OMER) can tell us which group is most powerful. Institutions...
- 01/14/2020
|
Omeros Co. (NASDAQ:OMER) Expected to Announce Quarterly Sales of $31.38 Million
- Equities research analysts forecast that Omeros Co. (NASDAQ:OMER) will report sales of $31.38 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Omeros’ earnings, with estimates ranging from $26.46 million to $36.30 million. Omeros posted sales of $22.02 million during the same quarter last year, which suggests a […]
- 01/11/2020
|
2019 Glomerulonephritis Pipeline Review, H2 - Biogen Inc, Omeros Corp, Pfizer Inc & Visterra Inc - ResearchAndMarkets.com
- DUBLIN--(BUSINESS WIRE)--The "Glomerulonephritis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV
- 01/09/2020
|
Hedge Funds Aren’t Crazy About Omeros Corporation (OMER) Anymore
- Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P; 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]
- 12/20/2019
|
myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab
- AMSTERDAM & SEATTLE--(BUSINESS WIRE)--myTomorrows, a global health technology company, and Omeros Corporation (Nasdaq: OMER), an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, today announced a collaboration. The collaboration broadens Omeros’ expanded access program to support availability of Omeros’ novel investigational complement inhibitor narsoplimab in several countries around the world. Narsoplimab is
- 12/18/2019
|
myTomorrows And Omeros Corporation Collaborate To Provide An Expanded Access Program For Narsoplimab
|
Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) last week presented new data directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology (ESMO) 2019 Immuno-Oncology Congress in Geneva, Switzerland. In addition to previously reported findings, which revealed enhanced anti-tumor immune responses in GPR174-deficient mice and synergism between adenosine receptor antagonists and GPR174 antagonists in promoting interleukin-2 (IL-2) and interferon-
- 12/16/2019
|
Omeros Highlights Presentation Of GPR174 Immuno-Oncology Data At ESMO Immuno-Oncology Congress Showing Inhibition Of Both Checkpoint And Tumor-Promoting Factors
|
Omeros Announces Full Exercise and Closing of Underwriter’s Option to Purchase Additional Shares
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, announced today the full exercise and closing of the sale of 572,518 shares of common stock to t
- 12/13/2019
|
Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva
- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology 2019 Immuno-Oncology Congress, which is being held December 11-14, 2019 in Geneva, Switzerland. In addition to previously presented ex vivo human and in vivo animal studies, the presentation will include new findings from human T-cells demonstrating that GPR174 inhibition results in downregulati
- 12/10/2019
|
75 Biggest Movers From Yesterday
|
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
- 12/05/2019
|
50 Stocks Moving In Thursday's Mid-Day Session
|
